We evaluated all patients in our HD unit and correlated the proposed risk factors between anti-HCV-positive and anti-HCV-negative patients. The patients were tested during 1991, 1992 (ELISA I; enzyme-linked immunosorbent assay), and by the end of 1994 (ELISA II). Among 223 patients (103 males and 120 females, mean age 54.3 ± 12.05 years) 83 (37.2%) were considered to be anti-HCV positive (44 males and 39 females, mean age 52.9 ± 12.2 years). Out of 37 hepatitis B surface antigen positive patients, 7 (18.9%) were anti-HCV positive too. The mean duration of the HD treatment was similar in both groups (7.6 ± 5.6 vs. 7.1 ± 5.9 years). Blood transfusion were applied in 44.5% of the anti-HCV-positive patients (1 dose in 27%, 2-4 in 40.6, 5-10 in 16.2, and > 10 doses in 16.2% of the patients) and in 55% of the anti-HCV-negative patients (1 dose in 26.6%, 2-4 in 35.6, 5-10 in 17.3, and > 10 doses in 20.5% of the patients). Transfusion policy and number of doses did not differ significantly between the two groups. The first anti-HCV-positive patients were diagnosed in 1991 (n = 20) and in 1992 (n = 3), and they were not dialyzed separately. During the next 2 years, routine testing for anti-HCV positivity and liver enzymes was not possible (we did not have the adequate equipment). Thereafter, 60 newly diagnosed anti-HCV-positive patients were registered in December 1994. We conclude that the isolation policy was the crucial risk factor for spread of HCV infection. Since then, all anti-HCV-positive patients were dialyzed separately with regular sterilization of the machines after every HD session. During the next 9 months (from February to November 1995), no additional anti-HCV-positive patients were detected. Our conclusion is in agreement with data that HCV infection is mainly a nosocomial infection [6] and that transmission could be successfully prevented by a rational isolation policy [7].
